Public affairs and market-access risk preparation for Chinese life-sciences companies entering the United States. We distinguish FDA scientific review, regulatory submissions, commercial access, and policy exposure, then organize executive materials and stakeholder questions. Regulatory counsel and scientific specialists own the submission and evidence; political outreach cannot replace FDA’s independent evaluation.
Reviewed: 2026-11-03
FDA drug approval depends on the relevant safety, effectiveness, and quality evidence. Establishment registration, drug listing, IND, NDA/BLA, reimbursement, and procurement are different processes. The appropriate specialists determine the product pathway; our mandate addresses the surrounding policy, stakeholder, and communications risks.
Separate product category, development stage, U.S. applicant, official process, technical owner, and counsel. Flag decisions requiring clinical, medical, statistical, CMC, or import expertise. Registration is not presented as approval.
Organize development history, data provenance, partners, manufacturing sites, ownership, and public concerns. Maintain a source index and approval record for public claims. Qualified specialists validate clinical, efficacy, and regulatory-status language.
Prepare stakeholder questions, executive Q&A, media responses, and policy context. If congressional or press attention arises, keep public affairs separate from formal scientific exchange with FDA while using consistent, verifiable facts.
Confirm the entity, business objective, deadline, actual request, and current counsel. Agree a safe channel before sharing sensitive records.
Verify the official provision, identity, operative-versus-proposed status, and supporting facts. Mark legal, technical, or scientific questions for the appropriate specialist.
Prepare the issue matrix, evidence index, first stakeholder Q&A, and an approval-gated plan. This is a preparation milestone, not an agency response or decision deadline.
Typical roles, not a ranking or a claim about any specific competitor.
| Provider | Role | Typical deliverable | Boundary |
|---|---|---|---|
| Large public affairs firm | Multi-issue policy and stakeholder execution | Policy campaign and engagement plan | Team, jurisdiction and actual mandate vary |
| Law firm / specialist counsel | Legal advice and representation | Legal opinion, filing, agreement | Communications execution needs an agreed scope |
| SIC Group public affairs | Evidence, policy context and stakeholder preparation | Source index, decision brief, Q&A | No legal representation or guaranteed result |
No. FDA independently evaluates the required evidence. Policy communications do not replace scientific requirements, a submission, or an agency decision.
This page covers public affairs and communications support. Regulatory submissions and specialist scientific work require the appropriate qualified teams and a separately defined scope.
No. The relevant product and process must be checked against the official status; establishment registration is not FDA approval of product safety and effectiveness.
Product category, indication or use, development stage, U.S. objective, existing regulatory and legal advisers, and deadline. Do not send identifiable patient information.
Describe your entity, objective, deadline, and current advisers. Do not include patient data, export-controlled material, or detailed trade secrets in an initial inquiry.
Contact the team